Replies to post #51245 on Regen BioPharma Inc (RGBP)

[Skiluc]

Shareholders wanting more NR2F6 answers: Listen Up.

Now dont be lazy. The following link contains 127+ articles with or from Regen Biopharma.

https://www.biospace.com/employer/536969/regen-biopharma-/

What im about to ask you to do should take all day, yet Its a simple assignment.

Requirements:
-note pad
-pen
-above link
-time and dedication

Assignment:
1. Follow above link to all 127 BioSpace articles from Regen
2. Read Every Article mentioning NR2F6 and NR2F2(say what?)
3. Write down anything and everything that catch’s your attention: good or bad.

Result: Clarity

Suggestion for maximizing result:
-Do this in chronological order.

Ill even do everyone interested a favor. Starts here:

https://www.biospace.com/article/releases/regen-biopharma-acquires-university-of-toronto-cancer-stem-cell-intellectual-property-/

Final Thoughts:
-be prepared to read alot(half the 128 articles aprox)
-this gave me fomo since I am aware of the advances in NR2F6 since most these publications.

Extra Credit:
-Find and figure out all the patented protections in NR2F6 that Regen Owns.

[crazy horse 0]

Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer

5/7/2021

Oncology Pharma Inc. (OTC PINK:ONPH) ONPH has entered into a licensing agreement with Regen BioPharma, Inc. for a technology utilizing small molecules to activate immune checkpoints for the treatment of colon cancer. The program entails identifying small molecules that inhibit the NR2F6 nuclear receptor.

https://www.biospace.com/article/releases/oncology-pharma-enters-into-license-agreement-for-small-molecules-intellectual-property-for-the-treatment-of-colon-cancer/